Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.
The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
People taking new weight-loss drugs say they curb cravings for booze, drugs, and nicotine. Did scientists inadvertently ...
The high list prices of these new weight loss drugs are costly for ... have been in short supply since 2022, but the FDA declared on Oct. 2 the drugs were no longer in shortage.
There has been a lot of conversation lately about if new weight loss drugs like Wegovy and Mounjaro should be covered by ...
Ozempic — or any of the GLP-1 class of diet drugs that includes Wegovy and Mounjaro — hasn’t just changed our nation’s ...
Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...
8d
Millions of obese Americans would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare or ...
About 7.4 million Americans with obesity could have insurance coverage for drugs like Wegovy if the Trump administration ...
the majority of those taking the drugs are not confident they can maintain the improvement after ending treatment, according to a new report. In a study of 500 patients by weight loss management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback